Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Gemina Laboratories Ltd. C.GLAB

Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. It operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.

Latest News

Gemina Labs Announces Addition to its IP Portfolio


Gemina Laboratories Sign First Strategic License Agreement


Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships


Gemina Announces Closing of $910,000 Convertible Note Financing


Gemina Labs Ltd Appoints Stifel as Financial Advisor


Canadian Securities Exchange Reports August 2023 Performance Figures


Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test...


Gemina Laboratories to Participate in Poster Session at American Association of Clinical...


Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in...


Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay...


Gemina Laboratories to Host Investor Webinar on March 30, 2023


Gemina Labs Appoints Diagnostic Strategist Martha Najib to the Board


Gemina Labs Announces Appointment of Healthcare Industry Leader Dr. Bola Grace to The Board of...


Gemina Labs Appoints Top Ranked UK Analyst and Scientist, Dr. Stefan Hamill as Vice President...


Gemina Labs Strategic Update: Respiratory Infections the Immediate Focus and New Strategic...